Mesoblast completes Phase 3 low back pain trial treatment as pivotal readout approaches
Mesoblast has completed treatment of 350 patients in its pivotal Phase 3 trial for chronic low back pain, with results expected in mid-2027.
Market Cap $207.8M
!
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Last update - 16.10pm 17/08/2026 (20 minute delay)
?
| Day | ||||||||
|---|---|---|---|---|---|---|---|---|
| Open | 54.0¢ | Day High | 54.5¢ | Day Low | 53.0¢ | |||
| Daily Volume | 113333 | |||||||
| Bids | Sellers | |||||
|---|---|---|---|---|---|---|
| Number | Price | Volume | Number | Price | Volume | |
| 0 | 53.0¢ | 670 | 0 | 54.0¢ | 4822 | |
Directors & Senior Management
| Mr. Chris Todd | Company Secretary & Group General Counsel |
| Mr. David Haslingden | Lead Independent Non-Executive Director |
| Ms. Erin J. Wallace | Independent Non-Executive Director |
| Dr. Gary Hilton Weiss | Non-Executive Chairman |
| Mr. Greg Yong | Group Chief Executive Officer |
| Mr. Jose de Sacadura | Group Chief Financial Officer |
| Mr. Randy A. Garfield | Independent Non-Executive Director |
Data source: ADVFN
